Research programme: selective androgen receptor modulators - Bristol-Myers Squibb/Ligand
Alternative Names: BMS 564929; BMS 665139Latest Information Update: 16 Jul 2016
At a glance
- Originator Bristol-Myers Squibb
- Developer Ligand Pharmaceuticals
- Class Hydantoins
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Muscular atrophy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Muscle-wasting in USA (PO)
- 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
- 15 Oct 2007 Bristol-Myers Squibb's SARM programme licensed to Pharmacopeia